

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 989 187 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
29.03.2000 Bulletin 2000/13

(51) Int Cl.7: **C12P 17/10, C12P 41/00**

(21) Application number: **99306750.3**

(22) Date of filing: **25.08.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Truesdell, Susan Jane**
Warwick, Rhode Island 02888 (US)


(74) Representative:
Simpson, Allison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
91 Wimpole Street
London W1M 8AH (GB)

(30) Priority: **28.08.1998 US 98255 P**


(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(54) **Microbial biotransformation using microorganisms of the genus *Monosporium* or *Thamostylum***

(57) The present invention relates to the use of microorganisms of the *Monosporium* and *Thamostylum* genera to diastereoselectively O-demethylate pharmaceutical intermediates, to produce compounds of the formulae:




I



III

FIG. 1



Description

BACKGROUND OF THE INVENTION

[0001] The present invention is directed to the use of microbial biotransformation to O-demethylate certain pharmaceutical intermediate compounds. More specifically, it is directed to the use of certain microorganisms to O-demethylate certain pharmaceutical intermediate compounds.

[0002] An article in *Analytica Chimica Acta* (1990) 233, 191-198 refers to the use of *Cunninghamella elegans* to demethylate certain n-propylnoraporphine compounds.

[0003] An article in *Biomedical and Environmental Mass Spectrometry* (1986) 13, 223-229 refers to the use of *Cunninghamella elegans* to produce potential metabolites of N-n-propyl noraporphine.

[0004] A review article published in *Enzyme and Microbial Technology* (1984) 6, 242-253 at pages 250-252 broadly reviews the use of certain microorganisms, e.g. fungal species such as *Cunninghamella*, *Aspergillus*, *Thamnostylum*, *Penicillium* and *Sepedonium* to O-dealkylate certain compounds.

[0005] Chapter 5.5 of *Biotransformations in Preparative Organic Chemistry* by H.G. Davies et al refers to the use of *Sepedonium chrysospermum* and *Cunninghamella elegans* to demethylate certain compounds, including vindoline and 10,11-dimethoxyaporphine.

[0006] An article in *Phytochemistry* (1997) 44 (8), 1479-1482, refers to the use of *Aspergillus niger* to produce (-)-pinoresinol through O-demethylation of (±)-eudesmin.

[0007] United States patent number 5,618,707 granted April 18, 1997 refers to the use of *Zygosaccharomyces bailii* ATCC 38924 to stereoselectively reduce a pentanoic acid compound to a phenyloxazolidinone product.


[0008] United States patent number 5,580,764 refers to the use of oxido/reductases from *Lactobacillus plantarum*, *Pichia haplophila*, *Candida utilis*, *Lactobacillus buchmans*, *Aspergillus flavus* and *Neurospora crassa* to reduce intermediates in the synthesis of carbonic anhydrase inhibitors.

Brief Description of the Drawings


[0009] FIGS 1-4 illustrate High Pressure Liquid Chromatography profiles generated using microbial biotransformation by 3 fungal cultures.

Summary of the Invention

[0010] In one embodiment, the present invention is directed to a process for the production of a compound of the formula:



from a compound of the formula




II

comprising selectively demethylating a compound of formula II in the presence of an enzyme derived from a culture of a microorganism of the genus *Monosporium*.

[0011] Preferred is the process wherein said microorganism is *Monosporium olivaceum*.


[0012] Also preferred is the process wherein said *Monosporium olivaceum* is *Monosporium olivaceum* ATCC 36300.

[0013] In another embodiment, the present invention is directed to a process for the preparation of a compound of the formula



III

from a compound of the formula




II

comprising selectively demethylating a compound of formula II in the presence of an enzyme derived from a microorganism of the genus *Thamnostylum*.


[0014] Preferred is the process wherein said microorganism is *Thamnostylum piriforme*.

[0015] Also preferred is the process wherein said *Thamnostylum piriforme* is *Thamnostylum piriforme* ATCC 8992.

[0016] In another embodiment, the present invention is directed to the use of a compound of the formula



to produce a compound of the formula




[0017] Preferred is the use wherein a compound of formula II is non-selectively demethylated.

Detailed Description of The Invention

[0018] This invention comprises using microorganisms to effect O-demethylation of an intermediate in the synthesis of CP-336,156 (estrogen agonist/osteoporosis). Use of microbes eliminates the chemical step which produces methyl bromide, a greenhouse gas which is difficult and expensive to trap, as a byproduct.

[0019] The biotransformation may be carried out using whole cell cultures of the microorganisms, cell extracts of the microorganisms, or purified enzymes from the microorganisms.

[0020] The starting material for this microbial biotransformation is CP-324,098, which is a mixture of the *cis* diastereomers. Three fungi have been found which carry out this reaction with different stereoselectivities. *Cunninghamella echinulata* O-demethylates both diastereomers to form the racemic mixture named CP-319,609, which is comprised of the diastereomers CP-336,156 and CP-335,992. *Monosporium olivaceum* and *Thamnostylum piriforme* act on only one of the diastereomers in CP-324,098 and yield a single diastereomer product as indicated below.



Cunninghamella echinulata

not diastereoselective

Thamnostylum piriforme

diastereoselective - "less desirable"
product
(CP-335,992)

Monosporium olivaceum

diastereoselective - desired product
(CP-336,156)

[0021] The starting material and the products made by these three organisms were determined by chiral HPLC as shown in FIGS 1-4. The final products of the reactions of all three microorganisms were isolated from the fermentation broth and characterized by NMR MS, and chiral HPLC to confirm their identity

Having described the invention in general terms, reference is now made to specific examples. It is to be understood that these examples are not meant to limit the present invention, the scope of which is determined by the appended claims

Monosporium olivaceum ATCC 36300 and *Thamnostylum piriforme* ATCC 8992 can be obtained from the American Type Culture Collection. A culture so obtained is added to a suitable growth medium and is incubated with shaking until growth occurs. The cultures thus prepared are used to inoculate slants. Portions of these slants are frozen as master stocks. The respective microorganisms are inoculated from slants into two flasks containing a growth medium whose composition is shown below. The fermentation is carried out at temperatures ranging from about 22 to about 32; however, for optimum results it is preferable to conduct the fermentation at about 28. The pH of the medium is controlled at about pH 6-7 by the use of suitable organic or inorganic buffers incorporated into the fermentation medium or by periodic addition of a base. Good growth of the microorganism is achieved within 48 to 72 hours. The contents of the flasks are transferred to a Fernbach flask containing fresh growth medium having the same composition as the previously used growth medium. Variation of the medium will alter the yield of the compound and its rate of production. The preferred media composition is set forth in the example section. After shaking for one additional day, a sterile-filtered solution of rapamycin in a suitable solvent such as dimethyl sulfoxide or dimethylformamide is added. The fermentation is continued for one to six days. It is preferred to continue the fermentation for about two days.

[0022] A suitable growth medium for use in the process of this invention will contain a source or sources of assimilable carbon, assimilable nitrogen and inorganic salts containing essential minerals. In general, many carbohydrates such as glucose, maltose, mannose, sucrose, starch, glycerin, millet jelly, molasses, soy bean and the like can be used as sources of assimilable carbon. Sources of assimilable nitrogen include such materials as yeast and casein hydrolysates, primary yeast, yeast extracts, cottonseed flour, soybean solids, wheat germ meat extracts, peptone, corn steep liquor, and ammonium salts. The inorganic salt nutrients which can be incorporated in the culture medium are the customary salts yielding sodium, iron, magnesium, potassium, cobalt, phosphate and the like. In general, of course, the techniques employed are not intended to be limiting.

[0023] Suitable grow media include (a) dextrose (20 g), yeast extract (5g), soy flour (5 g), NaCl (5g), K₂HPO₄ (5g)

and distilled water (1000 milliliters) where the pH is adjusted to 7.0 with aqueous HCl; (b) dextrin (10g), beef extract (3 g), ardamine pH (5g), N-Z amine type E (5 g), $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ (0.5 g), KH_2PO_4 (0.37 g), CaCO_3 (0.5 g), distilled water (1000 milliliters) where the pH is adjusted to 7.1 with aqueous HCl followed by a second stage of glucose (10 g), Hy-Case SF (2 g), beef extract (1 g), corn steep liquor (3 g), distilled water (1000 milliliters) where the pH is adjusted to 7.0; (c) glucose (10 g), corn steep liquor (6 g), KH_2PO_4 (3 g), CaCO_3 (3.5 g), Soybean oil (crude, 2.2 milliliters), yeast extract (2.5 g), distilled water (1000 milliliters) where the pH is adjusted to 7.0 - 7.3 with aqueous HCl; (d) malt syrup (20 g), soybean meal (5 g), casein (1 g), dried yeast (1 g), NaCl (5g), distilled water (1000 milliliters); (e) lactose (75 g), Pharmamedia (substitute yeast extract, 40 g), CaCO_3 (10 g), Na_2SO_3 (4 g), distilled water (1000 milliliters); (f) ISP #3; (h) ISP#4; (i) ISP#5 and the like.

Procedures

[0024] Cultures: *Cunninghamella echinulata* ATCC 9244 and ATCC 36190; *Monosporium olivaceum* ATCC 36300 and *Thamnostylum piriforme* ATCC 8992.

Biotransformation

[0025] Growth medium (inoculum & biotransformation stages):

glucose	20 g/l	pH to 7.0
soy flour or soy meal	5	
yeast extract	5	
NaCl	5	
K_2HPO_4	5	

[0026] 25 ml per 125 ml Erlenmeyer flask for inoculum and biotransformation. Inoculate from slants or frozen stock cultures into 25 ml of the medium above in a 125 ml Erlenmeyer flask and incubate with shaking at 28°C for 2-3 days. Transfer 2.5 ml into 25 ml of fresh broth in an Erlenmeyer flask and shake another day. Add CP-324,098 dissolved in DMSO and filter sterilized to a final concentration of 0.2 mg/ml. Additional substrate can be fed at 1 day intervals. Continue incubation with shaking for 1-6 days.

Extraction and purification

[0027] Broth was extracted with twice its volume of ethyl acetate in a separatory funnel. The phases were separated by centrifugation at 1000 x g for 5 minutes after which the upper ethyl acetate phase was carefully removed and evaporated to dryness. Methanol also works well as an extraction solvent. The product can be purified using solid phase extraction and preparative HPLC.


[0028] Chiral HPLC Assay

Column	Chiral OD, 4.6 x 250 mm (Daicel, Chiral Technologies)
Flow Rate	0.7 ml/min
Sample Size	20 μl
Concentration	0.1 mg/ml
Temperature	30°C
Detection	UV at 220 nm
Mobile Phase	100 ml ethyl alcohol (USP, dehydrated, 200 proof) plus 900 ml hexane plus 1 ml N,N'-diethyl amine


[0029] Samples are dissolved in ethanol,

Claims

1. A process for the production of a compound of the formula:




from a compound of the formula:




comprising selectively demethylating a compound of formula II in the presence of an enzyme derived from a culture of a microorganism of the genus *Monosporium*.

2. A process according to claim 1 wherein said microorganism is *Monosporium olivaceum*.
3. A process according to claim 2 wherein said *Monosporium olivaceum* is *Monosporium olivaceum* ATCC 36300.
4. A process for the production of a compound of the formula:




from a compound of the formula



20 comprising selectively demethylating a compound of formula II in the presence of an enzyme derived from a culture of a microorganism of the genus *Thamnostylum*.


- 25
5. A process according to claim 4 wherein said microorganisms is *Thamnostylum piriforme*.
 6. A process according to claim 5 wherein said *Thamnostylum* is *Thamnostylum piriforme* ATCC 8992.
 7. Use of a compound of the formula



45 to produce a compound of the formula

50

55



8. A use according to claim 7 wherein a compound of formula II is non-selectively O-dimethylated.






FIG. 1**FIG. 2**

FIG. 3**FIG. 4**



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 989 187 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
13.06.2001 Bulletin 2001/24

(51) Int Cl.7: **C12P 17/10**, C12P 41/00

(43) Date of publication A2:
29.03.2000 Bulletin 2000/13

(21) Application number: **99306750.3**

(22) Date of filing: **25.08.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Truesdell, Susan Jane**
Warwick, Rhode Island 02888 (US)


(74) Representative:
Simpson, Allison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1G 8ER (GB)

(30) Priority: **28.08.1998 US 98255 P**


(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(54) **Microbial biotransformation using microorganisms of the genus *Monosporium* or *Thamostylum***

(57) The present invention relates to the use of microorganisms of the *Monosporium* and *Thamostylum* genera to diastereoselectively O-demethylate pharmaceutical intermediates, to produce compounds of the formulae:




I



III

EP 0 989 187 A3

FIG. 1





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 30 6750
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	<p>DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SORBERA, L. A. ET AL: "CP-336156: treatment of osteoporosis" retrieved from STN Database accession no. 130:191316 XP002165660 * abstract * & DRUGS FUTURE (1998), 23(10), 1066-1070 ,</p> <p style="text-align: center;">--- -/-</p>	1-6	<p>C12P17/10 C12P41/00</p>
			<p>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</p> <p>C12P</p>
<p>INCOMPLETE SEARCH</p> <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: .</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		20 April 2001	Douschan, K
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			

EPO FORM 1503 (03.02) (P04C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number

EP 99 30 6750

Claim(s) searched completely:
1-6

Claim(s) searched incompletely:
7,8

Reason for the limitation of the search:

The subject-matter claimed in claims 7 and 8 is completely obscure and undefined, claiming the use of a compound II for the preparation of a compound I, without giving any specification how such a process is carried out. Since the said claims do not contain any reference to the processes claimed in claims 1-6, either, the said claims encompass ANY chemical or biochemical process of demethylation. Chemical processes, which are embraced by claims 7 and 8, are in no way supported by the description. Therefore claims 7 and 8 offend Art. 83 and 84 EPC, and a meaningful search for the claimed subject-matter is not possible.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 30 6750

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ROSATI, ROBERT L. ET AL: "Discovery and Preclinical Pharmacology of a Novel, Potent, Nonsteroidal Estrogen Receptor Agonist/Antagonist, CP-336156, a Diaryltetrahydronaphthalene" retrieved from STN Database accession no. 129:184100 XP002165661 * abstract * & J. MED. CHEM. (1998), 41(16), 2928-2931 -----	1-6	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.82 (P04C10)

BEST AVAILABLE COPY